Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: OPC 31260; Physuline

Latest Information Update: 08 Sep 2011

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Otsuka Pharmaceutical
  • Class Antihypertensives; Benzazepines; Cardiotonics
  • Mechanism of Action Vasopressin V2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hyponatraemia

Highest Development Phases

  • Marketed Hyponatraemia
  • Discontinued Hypertension; Polycystic kidney disease; Postmyocardial infarction

Most Recent Events

  • 21 Apr 2006 Preregistration for Hyponatraemia in Japan (unspecified route)
  • 21 Jan 2003 OPC 31260 is now called Mozavaptan
  • 11 Jan 2000 A preclinical study has been added to the Genitourinary Disorders pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top